Abstract
To investigate the effectiveness of thromboxane (Tx) synthase inhibitor in the prevention of experimental hepatic metastasis, an in vivo study was designed. Hepatic metastasis was brought about by injection of 1×105 cells of colon 38 tumor into the portal vein of C57 B1/65 mice. Seven groups (n=16 in each group) received different treatments: with TxA2 synthase inhibitor (sodium ozagrel), 5, 10 or 15 mg/kg BW before tumor inoculation, and daily for the following 3 days, (groups A, B and C, respectively); with acetyl salicylic acid (aspirin), 1.0, 1.5 or 2.0 mg/kg BW (groups C, D, and E, respectively); a control group, inoculated with vehicle only. Serum TxB2, a stable metabolite of TxA2, and prostaglandin F1α were measured. Labeling index for tumor proliferation by bromodeoxy-uridine radioimmuno-assay was also studied. Incidence of metastasis in groups A (60.5%), B (49.5%), C (43.0%), D (80.5%), E (66.0%) and F (58.4%) was less than that in the control group (100%). Tumor size, number or labeling index did not differ among the groups. Serum TxB2 (pg/ml) levels were significantly lower in all of the groups than in the control. Serum PGF1α levels in the groups with aspirin were lower than those in sodium ozagrel. Tx synthase inhibitor is effective in the prevention of experimental hepatic metastasis when it is given before and immediately after tumor inoculation. As Tx synthase inhibitor leaves metabolic pathway to PGI2 productionintact, it is more effective in the prevention of metastasis than aspirin since aspirin inhibits both thromboxane and PGI2.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Frost P, Levin B (1992) Clinical implication of metastatic process. Lancet 339: 1458–1461
Butler TP, Gullino PM (1975) Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35: 512–516
Glaves D, Huben RP, Weiss L (1988) Hematogenous dissemination of cells from human renal adenocarcinoma. Br J Cancer 57: 32–35
Post G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283: 139–146
Al-Mondhiry H (1984) Tumor interaction with hemostasis: the rational for the use of platelet inhibitors and anticoagulants in the treatment of cancer. Am J Hematol 16: 193–202
Gasic GJ, Gasic TB (1962) Removal of sialic acid from the cell coat in tumor cells and vascular endothelium and its effect on metastasis. Proc Natl Acad Sci USA 48: 1172–1177
Honn KV, Tang DG, Chen YQ (1992) Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 18: 392–415
Patrignani P, Filabozzi P, Patrono C (1982) Selective curmulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subject. J Clin Invest 69: 1366–1372
Sors H, Pradelles P, Dray F (1978) Analytical methods for thromboxane B2 measurement and validation of radioimmunoassay by gas liquid chromatography-mass spectrometry. Prostaglandins 16: 277–289
Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE (1991) Accelerated tumor growth after liver transplantation for hepatocellular carcinoma. Cancer 68: 2095–2100
Schabel RM Jr (1975) Concepts for systemic treatment of micrometastases. Cancer 35: 156–24
Hart I, Saini A (1992) Biology of tumour metastasis. Lancet 1: 1453–1457
Costantini V, Zacharski LR (1993) Fibrin and cancer. Thromb Haemostas 69: 406–414
Gasic GS (1984) Role of plasma, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 3: 99–116
Bockman RS (1983) Prostaglandins in cancer: a review. Cancer Invest 1: 485–493
Honn KV, Nockman RS, Marnett LJ (1981) Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 21: 883–864
Karmali RA (1986) Eicosanoids and cancer. Prog Clin Biol Res 222: 687–697
Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxydases. Proc Natl Acad Sci USA 72: 2994–2998
Flynn JT, Hellerman P, Shelly MA (1990) Zymosan-activated plasma-mediated thromboxane production by the perfused rabbit liver and isolated hepatocytes: involvement of calcium.Prostaglandins 40: 383–395
Nanji AA (1993) Thromboxane synthase and organ preference for metastases. N Engl J Med 329: 138–139
Spagnuolo PJ, Elliner JJ, Hassid A, Dunn MJ (1980) Thromboxane A2 mediates augmented polymophonuclear leukocyte adhesiveness. J Clin Invest 66: 406–414
Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, Narumiya S (1992) Cloning and expression of c DNA for mouse prostaglandine E receptor EP3 subtype. J Biol Chem 267: 6463–6466
Bunting S, Gryglewski R, Moncada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12: 897–913
Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res (1992) 52: 5575–5589
Costantini V, Fuschiotti P, Alelgrucci M, Nencil GG, Fioretti MC (1988) Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation. Cancer Chemother Pharmacol 22: 289–293
Honn KV, Cicone B, Skoff A (1981) A potent anti-metastatic agent. Science 212: 1270–1272
Honn KV, Meyer J (1991) Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. Biochem Biophys Res Commun 102: 1122–1129
Honn KV, Meyer J, Neagos G, Henderson T, Westley C, Ratanatharathorn V (1982) Control of tumor growth and metastatis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (Bay g 6575). In: Jamieson GA (ed) Interaction of platelets and tumor cells. Liss, New York, pp 295–331
Nigam S, Nakrezewicz (1990) Tumor cell proliferation by thromboxane A2: a receptor-mediated event. Adv Prostaglandin Thromboxane Leukot Res 21: 925–928
Stringfellow DA, Fitzpatrick FA (1979) Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells. Nature 282: 76–78
Furstenberg G, Marks F (1978) Indomethacin inhibition of cell proliferation induced by the phobol ester TPA is reversed by prostaglandine E2 in mouse epidermis in vivo. Biochem Biophys Res Commun 84: 1103–1111
Balch CM, Dougherty PA, Tilden AB (1984) Excessive prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95: 71–77
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yokoyama, I., Hayashi, S., Kobayashi, T. et al. Prevention of experimental hepatic metastasis with thromboxne synthase inhibitor. Res. Exp. Med. 195, 209–215 (1995). https://doi.org/10.1007/BF02576790
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02576790